[Health News] July 5, 2018
Developing into a future-oriented and global company
Miracell (CEO Shin Hyun-soon), a stem cell specialist company, recently revamped its corporate identity (CI).
The new CI embodies the company’s aspirations for growth as a future-oriented, global company.
The small circle symbolizes stem cells, signifying the convergence of technology and the miracles achieved by cells.
Miracell specializes in the wholesale of medical and scientific devices, including stem cell medical devices, cosmetics, trade, and e-commerce.
The company’s name, Miracell, is a portmanteau of “Miracel” and “Cell,” which means “miracle” in Latin.
As a stem cell specialist company that respects life and pursues a healthy lifestyle, Miracell embodies the company’s vision of creating miracles of healing, as embodied by the name “Mira.”
Miracell collaborates with domestic and international medical institutions to specialize in safe stem cell therapy, conducting research and development.
As a leading company in advanced medical technology that prioritizes not only disease treatment but also ethics and morality, Miracell aims to contribute to the development of hospitals and the improvement of public health.
Currently, Miracell’s stem cell treatment for diabetic lower extremity ischemia and knee osteoarthritis have been designated as limited new medical technologies and are eligible for new support from the Health and Medical Technology Research and Development Project.
Professor Chae Dong-sik (Orthopedic Surgery) at Catholic Kwandong University International St. Mary’s Hospital has demonstrated cartilage regeneration rates of over 70% using autologous bone marrow stem cell transplantation using Miracell’s SmartPRep2 BMAC system, a new medical technology.
Professor Eun-soo Park (Plastic Surgery) of Soonchunhyang University Bucheon Hospital is using Miracell’s SmartPrap 2 Bi-MAC system to provide autologous bone marrow stem cell therapy for diabetic lower extremity ischemia, giving hope to patients who previously had to undergo limb amputation.
CEO Hyun-soon Shin stated, “With this CI change, we will dedicate company-wide efforts to further advancing as a future-oriented, global company.”
By Joong-sun Lim jslim1971@bokuennews.com